BACKGROUND/AIMS: Autonomic nervous system imbalance is associated with metabolic diseases, including diabetes. Glibenclamide is an antidiabetic drug that acts by stimulating insulin secretion from pancreatic beta cells and is widely used in the treatment of type 2 diabetes. Since there is scarce data concerning autonomic nervous system activity and diabetes, the aim of this work was to test whether glibenclamide can improve autonomic nervous system activity and muscarinic acetylcholine receptor function in pre-diabetic obese male rats. METHODS: Pre-diabetes was induced by treatment with monosodium L-glutamate in neonatal rats. The monosodium L-glutamate group was treated with glibenclamide (2 mg/kg body weight /day) from weaning to 100 days of age, and the control group was treated with water. Body weight, food intake, Lee index, fasting glucose, insulin levels, homeostasis model assessment of insulin resistance, omeostasis model assessment of β-cell function, and fat tissue accumulation were measured. The vagus and sympathetic nerve electrical activity were recorded. Insulin secretion was measured in isolated islets challenged with glucose, acetylcholine, and the selective muscarinic acetylcholine receptor antagonists by radioimmunoassay technique. RESULTS: Glibenclamide treatment prevented the onset of obesity and diminished the retroperitoneal (18%) and epididymal (25%) fat pad tissues. In addition, the glibenclamide treatment also reduced the parasympathetic activity by 28% and glycemia by 20% in monosodium L-glutamate-treated rats. The insulinotropic effect and unaltered cholinergic actions in islets from monosodium L-glutamate groups were increased. CONCLUSION: Early glibenclamide treatment prevents monosodium L-glutamate-induced obesity onset by balancing autonomic nervous system activity.
BACKGROUND/AIMS: Autonomic nervous system imbalance is associated with metabolic diseases, including diabetes. Glibenclamide is an antidiabetic drug that acts by stimulating insulin secretion from pancreatic beta cells and is widely used in the treatment of type 2 diabetes. Since there is scarce data concerning autonomic nervous system activity and diabetes, the aim of this work was to test whether glibenclamide can improve autonomic nervous system activity and muscarinic acetylcholine receptor function in pre-diabetic obese male rats. METHODS: Pre-diabetes was induced by treatment with monosodium L-glutamate in neonatal rats. The monosodium L-glutamate group was treated with glibenclamide (2 mg/kg body weight /day) from weaning to 100 days of age, and the control group was treated with water. Body weight, food intake, Lee index, fasting glucose, insulin levels, homeostasis model assessment of insulin resistance, omeostasis model assessment of β-cell function, and fat tissue accumulation were measured. The vagus and sympathetic nerve electrical activity were recorded. Insulin secretion was measured in isolated islets challenged with glucose, acetylcholine, and the selective muscarinic acetylcholine receptor antagonists by radioimmunoassay technique. RESULTS:Glibenclamide treatment prevented the onset of obesity and diminished the retroperitoneal (18%) and epididymal (25%) fat pad tissues. In addition, the glibenclamide treatment also reduced the parasympathetic activity by 28% and glycemia by 20% in monosodium L-glutamate-treated rats. The insulinotropic effect and unaltered cholinergic actions in islets from monosodium L-glutamate groups were increased. CONCLUSION: Early glibenclamide treatment prevents monosodium L-glutamate-induced obesity onset by balancing autonomic nervous system activity.
Authors: J C de Oliveira; D X Scomparin; A E Andreazzi; R C S Branco; A G Martins; C Gravena; S Grassiolli; W Rinaldi; F B Barbosa; P C F Mathias Journal: J Neuroendocrinol Date: 2011-02 Impact factor: 3.627
Authors: Kathrin Maedler; Richard D Carr; Domenico Bosco; Richard A Zuellig; Thierry Berney; Marc Y Donath Journal: J Clin Endocrinol Metab Date: 2004-10-13 Impact factor: 5.958
Authors: Sandra Lucinei Balbo; Sabrina Grassiolli; Rosane Aparecida Ribeiro; Maria Lúcia Bonfleur; Clarice Gravena; Marcia do Nascimento Brito; Ana Eliza Andreazzi; Paulo Cezar de Freitas Mathias; Rosana Torrezan Journal: Endocrine Date: 2007-04 Impact factor: 3.633
Authors: Maria Sara Remedi; Harley T Kurata; Alexis Scott; F Thomas Wunderlich; Eva Rother; Andre Kleinridders; Ailing Tong; Jens C Brüning; Joseph C Koster; Colin G Nichols Journal: Cell Metab Date: 2009-02 Impact factor: 27.287
Authors: Cassia S Mizuno; Amar G Chittiboyina; Theodore W Kurtz; Harrihar A Pershadsingh; Mitchell A Avery Journal: Curr Med Chem Date: 2008 Impact factor: 4.530
Authors: Rosiane A Miranda; Rosana Torrezan; Júlio C de Oliveira; Luiz F Barella; Claudinéia C da Silva Franco; Patrícia C Lisboa; Egberto G Moura; Paulo C F Mathias Journal: J Endocrinol Date: 2016-04-25 Impact factor: 4.286